Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $10.00.

A number of equities analysts recently commented on the company. HC Wainwright reiterated a “neutral” rating and set a $6.00 price target on shares of Ventyx Biosciences in a report on Monday, November 11th. Oppenheimer reaffirmed an “outperform” rating and set a $9.00 price target (down previously from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th.

Insiders Place Their Bets

In other Ventyx Biosciences news, CEO Raju Mohan acquired 261,752 shares of the business’s stock in a transaction on Monday, November 25th. The stock was purchased at an average price of $2.01 per share, with a total value of $526,121.52. Following the acquisition, the chief executive officer now directly owns 2,175,028 shares of the company’s stock, valued at approximately $4,371,806.28. This trade represents a 13.68 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 18.18% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Palumbo Wealth Management LLC acquired a new stake in Ventyx Biosciences during the third quarter worth about $26,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Ventyx Biosciences by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock worth $30,000 after acquiring an additional 5,310 shares during the period. SG Americas Securities LLC bought a new position in Ventyx Biosciences in the second quarter valued at approximately $32,000. Intech Investment Management LLC acquired a new position in Ventyx Biosciences during the third quarter valued at approximately $42,000. Finally, The Manufacturers Life Insurance Company raised its position in Ventyx Biosciences by 41.1% during the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after purchasing an additional 7,096 shares in the last quarter. 97.88% of the stock is owned by institutional investors.

Ventyx Biosciences Price Performance

Shares of VTYX opened at $2.25 on Tuesday. The company has a market cap of $159.10 million, a PE ratio of -0.95 and a beta of 0.48. The firm has a 50-day moving average of $2.28 and a 200-day moving average of $2.44. Ventyx Biosciences has a one year low of $1.67 and a one year high of $11.48.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.